I think it depends on how strong the 4C is.
I'm on the other side of the coin - if we publish a $7m+ revenue for the quarter and announce we've onboarded an extra million cases per year, I think we are due for a re-rate to, at least, a $250m market cap. Annual run rate of $28m at $143m market cap on a high growth share is undervalued and investors might by looking for somewhere to put their money. No better place to put it than DW8.
- Forums
- ASX - By Stock
- KDY
- DW8 Growth
DW8 Growth, page-12108
-
- There are more pages in this discussion • 4,296 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KDY (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.834M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
KDY (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online